您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > AIM-100
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AIM-100
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AIM-100图片
CAS NO:873305-35-2
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议
500mg电议
1g电议

产品介绍
AIM-100 是一种有效的选择性 Ack1 抑制剂,IC50 为 21.58 nM。 AIM-100 还抑制 Tyr267 磷酸化。 AIM-100 不抑制其他激酶,包括 PI3 激酶和 AKT 亚家族成员。 AIM-100 具有抗癌作用。
Cas No.873305-35-2
别名5,6-二苯基-N-[[(2S)-四氢-2-呋喃基]甲基]呋喃并[2,3-D]嘧啶-4-胺,AIM 100;AIM100
化学名N-[[(2S)-oxolan-2-yl]methyl]-5,6-diphenylfuro[2,3-d]pyrimidin-4-amine
Canonical SMILESC1CC(OC1)CNC2=C3C(=C(OC3=NC=N2)C4=CC=CC=C4)C5=CC=CC=C5
分子式C23H21N3O2
分子量371.43
溶解度≥ 36 mg/mL in DMSO with gentle warming, ≥ 35.8 mg/mL in EtOH with gentle warming
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

AIM-100 is a small inhibitor of Ack1 tyrosine kinase with IC50 value of 24 nM [1].

AIM-100 mimicked ATP and inhibited the activity of Ack1 significantly and specifically. It showed no inhibition activity for the other 30 kinases including PI3-kinase and AKT, and showed a five-fold higher IC50 value for Lck. In MEF cells treated with EGF, AIM-100 caused a remarkable decrease of the activation of Ack1. In the human prostate cancer cells LNCaP and LAPC4, AIM-100 treatment resulted in an increase of G0/G1 cell phase and subsequent cell growth suppression. These effects of AIM-100 also exerted in the pancreatic cancer cells. AIM-100 induced apoptosis in Panc-1 cells at concentration of 10 μM. Moreover, AIM-100 inhibited cell growth with GI50 values of 7 to 8 μM in CD-18, Panc-1, OV90, MCF-7 and MDA-MB-468 cancer cells [1, 2].

References:
1. Mahajan K, Challa S, Coppola D, et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. The Prostate, 2010, 70(12): 1274-1285.
2. Mahajan K, Coppola D, Chen Y, et al. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. The American journal of pathology, 2012, 180(4): 1386-1393.